Sun Pharma subsidiary acquires Antibe Therapeutics for Rs 27 crores

Written by Ruchika Sharma Published On 2025-03-19T16:30:00+05:30 | Updated On 19 March 2025 4:30 PM IST

Sun Pharma subsidiary acquires Antibe Therapeutics for Rs 27 crores

Mumbai: In a recent BSE filing, Sun Pharmaceutical Industries Limited has informed that TARO Pharmaceuticals Inc., a subsidiary of Sun Pharmaceutical Industries Limited has completed 100 percent acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million.

Founded in 2009, Antibe is an Ontario, Canada incorporated corporation based in Ontario, Canada. It is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation. Consolidated revenue from operations of the Company for the previous three years is NIL.

Read also: Sun Pharma arm Taro Pharma to acquire 100% stake in Antibe Therapeutics

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

sun pharmasun pharma newsantibe therapeuticstaro pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751